Filtered By:
Cancer: Lung Cancer

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 1667 results found since Jan 2013.

Current Development of siRNA Bioconjugates: From Research to the Clinic
In this study, it was shown that the main factor determining the nature of the biodistribution of conjugates is their lipophilicity. Conjugates of siRNA with lower lipophilicity; i.e., derivatives of retinoic acid, lithocholic acid, and docosahexanoic acid with greater efficiency than cholesterol conjugates accumulated in the kidneys, bladder, and lungs of the mouse after subcutaneous injection (Biscans et al., 2018). This fact is consistent with previous data that showed that more lipophilic conjugates bind more efficiently to serum components, and thus are not excreted by the kidneys (Wolfrum et al., 2007; Osborn et al.,...
Source: Frontiers in Pharmacology - April 25, 2019 Category: Drugs & Pharmacology Source Type: research

Pulmonary Codelivery of Doxorubicin and siRNA by pH‐Sensitive Nanoparticles for Therapy of Metastatic Lung Cancer
In this study, DOX is conjugated onto polyethylenimine (PEI) by using cis‐aconitic anhydride (CA, a pH‐sensitive linker) to obtain PEI‐CA‐DOX conjugates. The PEI‐CA‐DOX/siRNA complex nanoparticles are formed spontaneously via electrostatic interaction between cationic PEI‐CA‐DOX and anionic siRNA. The drug release experiment shows that DOX releases faster at acidic pH than at pH 7.4. Moreover, PEI‐CA‐DOX/Bcl2 siRNA complex nanoparticles show higher cytotoxicity and apoptosis induction in B16F10 cells than those treated with either DOX or Bcl2 siRNA alone. When the codelivery systems are directly sprayed...
Source: Small - July 1, 2015 Category: Nanotechnology Authors: Caina Xu, Ping Wang, Jingpeng Zhang, Huayu Tian, Kinam Park, Xuesi Chen Tags: Full Paper Source Type: research

EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
CONCLUSION: We conclude that co-delivery of Dox and Bcl-2-siRNA by tumor-targeted EGF-PEAL NPs could significantly inhibit lung cancer growth. PMID: 26739487 [PubMed - as supplied by publisher]
Source: Drug Delivery - February 16, 2016 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research

Cholesterol-grafted chitosan micelles as a nanocarrier system for drug-siRNA co-delivery to the lung cancer cells.
Abstract Combined delivery of a therapeutic small interfering RNA (siRNA) and a chemotherapeutic agent to cancer cells is promising as anticancer therapy, which could offer enhanced cell killing potential and low side effect. However, simultaneous delivery to tumor is challenging. In our study, cholesterol-modified low molecular weight chitosan (MW ~ 15 kDa) was employed as a self-assembled delivery system for both siRNA and a hydrophobic chemotherapeutic agent, curcumin to cancer cells. The siRNA/curcumin loaded nanoparticles (C-CCM/siRNA) were physico-chemically characterized for particle size (165 ± ...
Source: International Journal of Biological Macromolecules - June 25, 2018 Category: Biochemistry Authors: Muddineti OS, Shah A, Rompicharla SVK, Ghosh B, Biswas S Tags: Int J Biol Macromol Source Type: research

Construction of PEI ‐EGFR‐PD‐L1‐siRNA dual functional nano‐vaccine and therapeutic efficacy evaluation for lung cancer
ConclusionOur constructed lipid nanoparticles of tumor targeted therapy gene siRNA combination had the ability to target cells in vitro and downregulate the expression of PD-L1, realizing the tumor-specific expression of immune-stimulating cytokines, which is a highly efficient and safe targeted therapy nano-vaccine.
Source: Thoracic Cancer - September 19, 2022 Category: Cancer & Oncology Authors: Guixue Yang, Dong Zhou, Yin Dai, Yanqi Li, Jiang Wu, Quanxing Liu, Xufeng Deng Tags: ORIGINAL ARTICLE Source Type: research

Abstract 4571: Antitumor effects of an antibody (cetuximab)-targeted nanoparticle containing siRNA against EGFR
Conclusions: NPs containing full antibodies as targeting agents and siRNA payloads can be formulated into well defined, stable experimental therapeutics. The NP system used here has a pH-tunable 5-nPBA that allows for targeting and stabilizing the NP at a physiologic pH of 7.4. The targeting agent and PEG coating is able to detach from the NP at acidic pH like those found in endosomes, enabling the siRNA payload to escape and reach its site of action within the cell. These NPs produce significant tumor regression in vivo that is superior to CTX alone. Citation Format: Dorothy W. Pan, Mark E. Davis. Antitumor effects of an ...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Pan, D. W., Davis, M. E. Tags: Experimental and Molecular Therapeutics Source Type: research

Polyelectrolyte complexes of hTERT siRNA and polyethyleneimine: Effect of degree of PEG grafting on biological and cellular activity.
Authors: Safari F, Tamaddon AM, Zarghami N, Abolmali S, Akbarzadeh A Abstract Gene silencing by siRNA (short interfering RNA)-targeted human telomerase reverse transcriptase (hTERT) is considered a successful strategy for cancer gene therapy. Polyelectrolyte complexes (PEC) of siRNA and cationic polymers such as polyethyleneimine (PEI) have been widely used for cellular transfection; however, they demonstrate some disadvantages such as cytotoxicity and extracellular matrix restrictions. PEG grafting technology was used in an attempt to improve the biocompatibility of PECs. Considering that this technology may compr...
Source: Artificial Cells, Nanomedicine and Biotechnology - December 12, 2015 Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research

Anti-tumor effects of combined doxorubicin and siRNA for pulmonary delivery
In this study, combined doxorubicin (DOX) and Bcl2 siRNA was employed for cancer therapy using polyethylenimine (PEI) as the carrier of Bcl2 siRNA. Most of the DOX and siRNA possessed high cellular uptake efficiency in B16F10 cells, which was proved by FCM and CLSM analysis. Real-time PCR showed that PEI/Bcl2 siRNA exhibited high gene silencing efficiency with 70% Bcl2 mRNA being knocked down. The combination of DOX and siRNA could enhance the cell proliferation inhibition and the cell apoptosis against B16F10 cells compared to free DOX or PEI/Bcl2 siRNA. Furthermore, the biodistribution of DOX and siRNA via pulmonary admi...
Source: Chinese Chemical Letters - December 15, 2016 Category: Chemistry Source Type: research

Aerosol delivery of star polymer-siRNA nanoparticles as a therapeutic strategy to inhibit lung tumor growth
Biomaterials. 2022 Apr 23;285:121539. doi: 10.1016/j.biomaterials.2022.121539. Online ahead of print.ABSTRACTLung cancer is a major contributor to cancer-related death worldwide. siRNA nanomedicines are powerful tools for cancer therapeutics. However, there are challenges to overcome to increase siRNA delivery to solid tumors, including penetration of nanoparticles into a complex microenvironment following systemic delivery while avoiding rapid clearance by the reticuloendothelial system, and limited siRNA release from endosomes once inside the cell. Here we characterized cell uptake, intracellular trafficking, and gene si...
Source: Biomaterials - May 2, 2022 Category: Materials Science Authors: Z Ma S W Wong H Forgham L Esser M Lai M N Leiske K Kempe G Sharbeen J Youkhana F Mansfeld J F Quinn P A Phillips T P Davis M Kavallaris J A McCarroll Source Type: research

Study on co-delivery of pemetrexed disodium and Bcl-2 siRNA by poly- γ-glutamic acid-modified cationic liposomes for the inhibition of NSCLC
Drug Dev Ind Pharm. 2023 Feb 20:1-18. doi: 10.1080/03639045.2023.2182125. Online ahead of print.ABSTRACTDue to the complexity of pathophysiology of non-small cell lung cancer (NSCLC) and susceptibility of single chemotherapy to drug resistance, the combination of drugs and small interfering RNA (siRNA) may produce desired therapeutic effect on NSCLC through action of multiple pathways. We designed to develop poly-γ-glutamic acid-modified cationic liposomes (γ-PGA-CL) to co-deliver pemetrexed disodium (PMX) and siRNA to treat NSCLC. Firstly, γ-PGA was modified on surface of PMX and siRNA co-loaded cationic liposomes by e...
Source: Drug Development and Industrial Pharmacy - February 21, 2023 Category: Drugs & Pharmacology Authors: Huang Xiaoyu Song Ruonan Wang Xiao Kongfang He Rumeng Shan Xie Fei Guihua Huang Source Type: research

Cabazitaxel-loaded human serum albumin nanoparticles combined with TGF β-1 siRNA lipid nanoparticles for the treatment of paclitaxel-resistant non-small cell lung cancer
ConclusionsThe antitumor effect of CTX-HSA-NPs on paclitaxel-resistant NSCLC was higher than that of CTX-Tween, and the toxicity was lower than that of CTX-Tween. TGF β-1 siRNA LNP can treat paclitaxel-resistant NSCLC by inhibiting the express ofTGF β-1 mRNA. The combined treatment of TGF β-1 siRNA LNP and CTX-HSA-NPs could effectively improve the antitumor efficacy of paclitaxel-resistant NSCLC. A combination therapy of chemotherapy and nucleic acid drugs could be an effective approach for treating paclitaxel-resistant NSCLC.
Source: Cancer Nanotechnology - July 29, 2023 Category: Cancer & Oncology Source Type: research

086 * A NEW STRATEGY IN THE TREATMENT OF CHEMORESISTANT LUNG ADENOCARCINOMA VIA siRNA SPECIFIC SILENCING OF SRF, E2F1, SURVIVIN, HIF AND STAT 3
Conclusions: Our study proposed a new alternative in the treatment of chemoresistant NSCLC. Via siRNA specific silencing complex an accurate suppression of various chemoresistant cell lines can be achieved. Therefore, siRNA might represent an effective transient individualized regimen in the treatment of NSCLC as well an important platform for new chemotherapeutics.
Source: Interactive CardioVascular and Thoracic Surgery - September 18, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Stoleriu, M. G., Steger, V., Mustafi, M., Schneider, W., Wendel, H. P., Walker, T., Schlensak, C. Tags: Thoracic experimental Source Type: research